Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte?

I. Melero, Richard Geoffrey Vile, M. P. Colombo

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Adoptive transfer of autologous dendritic cells (DC) presenting tumor-associated antigens initiate and sustain an immune response which eradicate murine malignancies. Based on these observations, several clinical trials are in progress testing safety and efficacy with encouraging preliminary reports. In these approaches, ex vivo incubation of DC with a source of tumor antigens is required to load the relevant antigenic epitopes on the adequate antigen presenting molecules. Recent data show that in some instances exogenous DC artificially injected into malignant tissue or endogenous DC attracted to the tumor nodule by means of gene transfer of GM-CSF and CD40L into malignant cells result in efficacious antitumor immunity. In the case of intratumoral injection of DC the procedure is curative only if DC had been genetically engineered to produce IL-12, IL-6 or to express CD40L. Evidence has been obtained showing that intratumoral DC can capture and process tumor antigens to be presented to T-lymphocytes. Although the exact mechanisms of tumor antigen acquisition by DC are still unclear, available data suggest a role for heat shock proteins released from dying malignant cells and for the internalization of tumor-derived apoptotic bodies. Roles for tumor necrosis versus apoptosis are discussed in light of the 'danger theory'.

Original languageEnglish (US)
Pages (from-to)1167-1170
Number of pages4
JournalGene Therapy
Volume7
Issue number14
StatePublished - 2000

Fingerprint

Neoplasm Antigens
Dendritic Cells
CD40 Ligand
Neoplasms
Adoptive Transfer
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
Heat-Shock Proteins
Epitopes
Immunity
Interleukin-6
Necrosis
Clinical Trials
Apoptosis
T-Lymphocytes
Safety
Antigens
Injections
Genes

Keywords

  • CD40
  • Cytokines
  • Dentritic cells
  • Gene therapy
  • Heat shock proteins
  • Immunotherapy

ASJC Scopus subject areas

  • Genetics

Cite this

Feeding dendritic cells with tumor antigens : Self-service buffet or a la carte? / Melero, I.; Vile, Richard Geoffrey; Colombo, M. P.

In: Gene Therapy, Vol. 7, No. 14, 2000, p. 1167-1170.

Research output: Contribution to journalArticle

@article{4d01ee66daed4db19b736c107adc43ff,
title = "Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte?",
abstract = "Adoptive transfer of autologous dendritic cells (DC) presenting tumor-associated antigens initiate and sustain an immune response which eradicate murine malignancies. Based on these observations, several clinical trials are in progress testing safety and efficacy with encouraging preliminary reports. In these approaches, ex vivo incubation of DC with a source of tumor antigens is required to load the relevant antigenic epitopes on the adequate antigen presenting molecules. Recent data show that in some instances exogenous DC artificially injected into malignant tissue or endogenous DC attracted to the tumor nodule by means of gene transfer of GM-CSF and CD40L into malignant cells result in efficacious antitumor immunity. In the case of intratumoral injection of DC the procedure is curative only if DC had been genetically engineered to produce IL-12, IL-6 or to express CD40L. Evidence has been obtained showing that intratumoral DC can capture and process tumor antigens to be presented to T-lymphocytes. Although the exact mechanisms of tumor antigen acquisition by DC are still unclear, available data suggest a role for heat shock proteins released from dying malignant cells and for the internalization of tumor-derived apoptotic bodies. Roles for tumor necrosis versus apoptosis are discussed in light of the 'danger theory'.",
keywords = "CD40, Cytokines, Dentritic cells, Gene therapy, Heat shock proteins, Immunotherapy",
author = "I. Melero and Vile, {Richard Geoffrey} and Colombo, {M. P.}",
year = "2000",
language = "English (US)",
volume = "7",
pages = "1167--1170",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "14",

}

TY - JOUR

T1 - Feeding dendritic cells with tumor antigens

T2 - Self-service buffet or a la carte?

AU - Melero, I.

AU - Vile, Richard Geoffrey

AU - Colombo, M. P.

PY - 2000

Y1 - 2000

N2 - Adoptive transfer of autologous dendritic cells (DC) presenting tumor-associated antigens initiate and sustain an immune response which eradicate murine malignancies. Based on these observations, several clinical trials are in progress testing safety and efficacy with encouraging preliminary reports. In these approaches, ex vivo incubation of DC with a source of tumor antigens is required to load the relevant antigenic epitopes on the adequate antigen presenting molecules. Recent data show that in some instances exogenous DC artificially injected into malignant tissue or endogenous DC attracted to the tumor nodule by means of gene transfer of GM-CSF and CD40L into malignant cells result in efficacious antitumor immunity. In the case of intratumoral injection of DC the procedure is curative only if DC had been genetically engineered to produce IL-12, IL-6 or to express CD40L. Evidence has been obtained showing that intratumoral DC can capture and process tumor antigens to be presented to T-lymphocytes. Although the exact mechanisms of tumor antigen acquisition by DC are still unclear, available data suggest a role for heat shock proteins released from dying malignant cells and for the internalization of tumor-derived apoptotic bodies. Roles for tumor necrosis versus apoptosis are discussed in light of the 'danger theory'.

AB - Adoptive transfer of autologous dendritic cells (DC) presenting tumor-associated antigens initiate and sustain an immune response which eradicate murine malignancies. Based on these observations, several clinical trials are in progress testing safety and efficacy with encouraging preliminary reports. In these approaches, ex vivo incubation of DC with a source of tumor antigens is required to load the relevant antigenic epitopes on the adequate antigen presenting molecules. Recent data show that in some instances exogenous DC artificially injected into malignant tissue or endogenous DC attracted to the tumor nodule by means of gene transfer of GM-CSF and CD40L into malignant cells result in efficacious antitumor immunity. In the case of intratumoral injection of DC the procedure is curative only if DC had been genetically engineered to produce IL-12, IL-6 or to express CD40L. Evidence has been obtained showing that intratumoral DC can capture and process tumor antigens to be presented to T-lymphocytes. Although the exact mechanisms of tumor antigen acquisition by DC are still unclear, available data suggest a role for heat shock proteins released from dying malignant cells and for the internalization of tumor-derived apoptotic bodies. Roles for tumor necrosis versus apoptosis are discussed in light of the 'danger theory'.

KW - CD40

KW - Cytokines

KW - Dentritic cells

KW - Gene therapy

KW - Heat shock proteins

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033930588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033930588&partnerID=8YFLogxK

M3 - Article

C2 - 10918484

AN - SCOPUS:0033930588

VL - 7

SP - 1167

EP - 1170

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 14

ER -